Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

349 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cunningham D, et al. N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025. N Engl J Med. 2004. PMID: 15269313 Clinical Trial.
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.
Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G. Gianni AM, et al. N Engl J Med. 1997 May 1;336(18):1290-7. doi: 10.1056/NEJM199705013361804. N Engl J Med. 1997. PMID: 9113932 Clinical Trial.
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
Cascinu S, Graziano F, Ferraù F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R. Cascinu S, et al. Ann Oncol. 2002 May;13(5):716-20. doi: 10.1093/annonc/mdf091. Ann Oncol. 2002. PMID: 12075739 Clinical Trial.
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J; Aranesp 980297 Study Group. Vansteenkiste J, et al. J Natl Cancer Inst. 2002 Aug 21;94(16):1211-20. doi: 10.1093/jnci/94.16.1211. J Natl Cancer Inst. 2002. PMID: 12189224 Clinical Trial.
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group. Green MD, et al. Ann Oncol. 2003 Jan;14(1):29-35. doi: 10.1093/annonc/mdg019. Ann Oncol. 2003. PMID: 12488289 Clinical Trial.
PATIENTS AND METHODS: Patients (n = 157) were randomized to receive either a single 6 mg subcutaneous (s.c.) injection of pegfilgrastim or daily 5 mg/kg s.c. injections of filgrastim, after doxorubicin and docetaxel chemotherapy (60 mg/m(2) and 75 mg/m(2), respectiv …
PATIENTS AND METHODS: Patients (n = 157) were randomized to receive either a single 6 mg subcutaneous (s.c.) injection of pegfilgrast …
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Moroni M, et al. Lancet Oncol. 2005 May;6(5):279-86. doi: 10.1016/S1470-2045(05)70102-9. Lancet Oncol. 2005. PMID: 15863375 Clinical Trial.
By contrast, one of 21 non-responders assessable by FISH had an increased EGFR copy number (p<0.0001 for responders vs non-responders, Fisher's exact test). ...
By contrast, one of 21 non-responders assessable by FISH had an increased EGFR copy number (p<0.0001 for responders vs non-responders, Fi …
Treatment of metastatic neuroendocrine carcinomas based on WHO classification.
Artale S, Giannetta L, Cerea G, Maggioni D, Pedrazzoli P, Schiavetto I, Napolitano M, Veronese S, Bramerio E, Gambacorta M, Vanzulli A, Pisconti S, Pugliese R, Siena S. Artale S, et al. Anticancer Res. 2005 Nov-Dec;25(6C):4463-9. Anticancer Res. 2005. PMID: 16334127
Cetuximab for treatment of metastatic colorectal cancer.
Cerea G, Ricotta R, Schiavetto I, Maugeri MR, Sartore-Bianchi A, Moroni M, Artale S, Siena S. Cerea G, et al. Ann Oncol. 2006 Jun;17 Suppl 7:vii66-7. doi: 10.1093/annonc/mdl954. Ann Oncol. 2006. PMID: 16760297
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA. Pinto C, et al. Ann Oncol. 2007 Mar;18(3):510-7. doi: 10.1093/annonc/mdl459. Epub 2006 Dec 12. Ann Oncol. 2007. PMID: 17164226 Clinical Trial.
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Benvenuti S, et al. Cancer Res. 2007 Mar 15;67(6):2643-8. doi: 10.1158/0008-5472.CAN-06-4158. Cancer Res. 2007. PMID: 17363584
349 results
Jump to page
Feedback